PSC
EVFM

Piper Sandler & Co’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Piper Sandler & Co’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-587
Closed -$475K – 139
2015
Q2 		$475K Sell
587
-2,784
-83% -$1.79M 0.28% 34
2015
Q1 		$2.49M Sell
3,371
-1,508
-31% -$964K 1.03% 16
2014
Q4 		$3.29M Buy
+4,879
New +$3.69M 1.6% 14

Other funds holding EVFM

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Piper Sandler & Co's EVFM Position: Q3 2015 in Review

Piper Sandler & Co sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2015, closing a stake of 587 shares — an estimated $475K sold.

Piper Sandler & Co first reported a position in EVFM in Q4 2014 and held it in 3 quarters. The position peaked at $3.29M in Q4 2014. 29 funds tracked by Wall St. Rank hold EVFM as of Q3 2015.

  • Piper Sandler & Co reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 587 Evofem Biosciences, Inc. Common Stock shares in Q3 2015, an estimated $475K.
  • Piper Sandler & Co first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 3 quarters.
  • Piper Sandler & Co's Evofem Biosciences, Inc. Common Stock position peaked at $3.29M in Q4 2014.
  • 29 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2015.

Based on Piper Sandler & Co's 13F filing for Q3 2015, filed 16 Nov 2015.